Abstract
Oxidative damage is a major feature of Alzheimers disease pathophysiology. Instead of succumbing to these oxidative abnormalities, neurons upregulate antioxidant defenses, which suggest a novel balance in oxidant homeostasis in Alzheimers disease. Evidence indicates that in the initial phase of Alzheimers disease development, amyloid-β deposition and hyperphosphorylated τ are consequences of oxidative stress and function as a primary line of antioxidant defense. However, during the progression of the disease, the antioxidant activity of both agents evolves into pro-oxidant, representing a typical gain-of-function transformation. This transformation is due to an increase in reactive species and a decrease in clearance mechanisms. However, the notion that amyloid-β and hyperphosphorylated t function as protective components in the early stages of Alzheimers disease brings into serious question the rationale of current therapeutic strategies aimed to remove both amyloid-β and hyperphosphorylated τ.
Keywords: alzheimer disease, amyloid, oxidative stress, reactive oxygen species, tau
Current Neurovascular Research
Title: A Second Look into the Oxidant Mechanisms in Alzheimers Disease
Volume: 2 Issue: 2
Author(s): Paula I. Moreira, Catarina R. Oliveira, Maria S. Santos, Akihiko Nunomura, Kazuhiro Honda, Xiongwei Zhu, Mark A. Smith and George Perry
Affiliation:
Keywords: alzheimer disease, amyloid, oxidative stress, reactive oxygen species, tau
Abstract: Oxidative damage is a major feature of Alzheimers disease pathophysiology. Instead of succumbing to these oxidative abnormalities, neurons upregulate antioxidant defenses, which suggest a novel balance in oxidant homeostasis in Alzheimers disease. Evidence indicates that in the initial phase of Alzheimers disease development, amyloid-β deposition and hyperphosphorylated τ are consequences of oxidative stress and function as a primary line of antioxidant defense. However, during the progression of the disease, the antioxidant activity of both agents evolves into pro-oxidant, representing a typical gain-of-function transformation. This transformation is due to an increase in reactive species and a decrease in clearance mechanisms. However, the notion that amyloid-β and hyperphosphorylated t function as protective components in the early stages of Alzheimers disease brings into serious question the rationale of current therapeutic strategies aimed to remove both amyloid-β and hyperphosphorylated τ.
Export Options
About this article
Cite this article as:
Moreira I. Paula, Oliveira R. Catarina, Santos S. Maria, Nunomura Akihiko, Honda Kazuhiro, Zhu Xiongwei, Smith A. Mark and Perry George, A Second Look into the Oxidant Mechanisms in Alzheimers Disease, Current Neurovascular Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567202053586758
DOI https://dx.doi.org/10.2174/1567202053586758 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
FK506-Binding Proteins and Their Diverse Functions
Current Molecular Pharmacology Human Papillomavirus E7 Oncoprotein Promotes Proliferation and Migration through the Transcription Factor E2F1 in Cervical Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry The Complex Actions of Statins in Brain and their Relevance for Alzheimer`s Disease Treatment: An Analytical Review
Current Alzheimer Research The Effects of Cantharidin and Cantharidin Derivates on Tumour Cells
Anti-Cancer Agents in Medicinal Chemistry Non-Genotoxic p53-Activators and their Significance as Antitumor Therapy of Future
Current Medicinal Chemistry Malignant Mesothelioma: Cell Survival Pathways and Radiation Therapy
Current Respiratory Medicine Reviews p35 Deficiency Accelerates HMGB-1-mediated Neuronal Death in the Early Stages of an Alzheimer's disease Mouse Model
Current Alzheimer Research Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders
Mini-Reviews in Medicinal Chemistry Animal Models for Testing Anti-Prion Drugs
Current Topics in Medicinal Chemistry The Effects of Weightlessness on the Human Organism and Mammalian Cells
Current Molecular Medicine AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species
Current Pharmaceutical Design mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry Endocannabinoids as Regulators of Transient Receptor Potential (TRP)Channels: a Further Opportunity to Develop New Endocannabinoid-Based Therapeutic Drugs
Current Medicinal Chemistry Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors
Current Drug Targets Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide
Current Pharmaceutical Design Mitochondrial Permeability Transition Pore as a Suitable Targ e t for Neuroprotective Agents Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Antitumor Activities of Interleukin-27 on Melanoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Polyphenols: Well Beyond The Antioxidant Capacity: Gallic Acid and Related Compounds as Neuroprotective Agents: You are What You Eat!
Current Pharmaceutical Biotechnology Determining the Oligomer Number of Native GPCR Using Florescence Correlation Spectroscopy and Drug-Induced Inactivation-Reactivation
Current Pharmaceutical Biotechnology Applications of High Content Screening in Life Science Research
Combinatorial Chemistry & High Throughput Screening